c-MYC amplification and c-myc protein expression in pancreatic acinar cell carcinomas. New insights into the molecular signature of these rare cancers

Virchows Arch. 2018 Oct;473(4):435-441. doi: 10.1007/s00428-018-2366-5. Epub 2018 May 2.

Abstract

The molecular alterations of pancreatic acinar cell carcinomas (ACCs) and mixed acinar-neuroendocrine carcinomas (MANECs) are not completely understood, and the possible role of c-MYC amplification in tumor development, progression, and prognosis is not known. We have investigated c-MYC gene amplification in a series of 35 ACCs and 4 MANECs to evaluate its frequency and a possible prognostic role. Gene amplification was investigated using interphasic fluorescence in situ hybridization analysis simultaneously hybridizing c-MYC and the centromere of chromosome 8 probes. Protein expression was immunohistochemically investigated using a specific monoclonal anti-c-myc antibody. Twenty cases had clones with different polysomies of chromosome 8 in absence of c-MYC amplification, and 5 cases had one amplified clone and other clones with chromosome 8 polysomy, while the remaining 14 cases were diploid for chromosome 8 and lacked c-MYC amplification. All MANECs showed c-MYC amplification and/or polysomy which were observed in 54% pure ACCs. Six cases (15.3%) showed nuclear immunoreactivity for c-myc, but only 4/39 cases showed simultaneous c-MYC amplification/polysomy and nuclear protein expression. c-myc immunoreactivity as well as c-MYC amplification and/or chromosome 8 polysomy was not statistically associated with prognosis. Our study demonstrates that a subset of ACCs shows c-MYC alterations including gene amplification and chromosome 8 polysomy. Although they are not associated with a different prognostic signature, the fact that these alterations are present in all MANECs suggests a role in the acinar-neuroendocrine differentiation possibly involved in the pathogenesis of MANECs.

Keywords: Acinar cell carcinoma; Amplification; MANEC; MiNEN; Pancreas; Prognosis; c-myc.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Aneuploidy
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / genetics*
  • Carcinoma, Acinar Cell / chemistry
  • Carcinoma, Acinar Cell / genetics*
  • Carcinoma, Acinar Cell / pathology
  • Carcinoma, Acinar Cell / therapy
  • Cell Differentiation
  • Chromosomes, Human, Pair 8
  • Female
  • Gene Amplification*
  • Genetic Predisposition to Disease
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization, Fluorescence
  • Male
  • Middle Aged
  • Neoplasms, Complex and Mixed / chemistry
  • Neoplasms, Complex and Mixed / genetics*
  • Neoplasms, Complex and Mixed / pathology
  • Neoplasms, Complex and Mixed / therapy
  • Neuroendocrine Tumors / chemistry
  • Neuroendocrine Tumors / genetics*
  • Neuroendocrine Tumors / pathology
  • Neuroendocrine Tumors / therapy
  • Pancreatic Neoplasms / chemistry
  • Pancreatic Neoplasms / genetics*
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / therapy
  • Phenotype
  • Prognosis
  • Proto-Oncogene Proteins c-myc / analysis
  • Proto-Oncogene Proteins c-myc / genetics*
  • Transcriptome*

Substances

  • Biomarkers, Tumor
  • MYC protein, human
  • Proto-Oncogene Proteins c-myc